GLPG vs. JAZZ, ELAN, SMMT, MDGL, CYTK, VKTX, OGN, NUVL, BBIO, and APLS
Should you be buying Galapagos stock or one of its competitors? The main competitors of Galapagos include Jazz Pharmaceuticals (JAZZ), Elanco Animal Health (ELAN), Summit Therapeutics (SMMT), Madrigal Pharmaceuticals (MDGL), Cytokinetics (CYTK), Viking Therapeutics (VKTX), Organon & Co. (OGN), Nuvalent (NUVL), BridgeBio Pharma (BBIO), and Apellis Pharmaceuticals (APLS). These companies are all part of the "pharmaceutical preparations" industry.
Jazz Pharmaceuticals (NASDAQ:JAZZ) and Galapagos (NASDAQ:GLPG) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, community ranking, media sentiment and dividends.
Jazz Pharmaceuticals has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Comparatively, Galapagos has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500.
89.1% of Jazz Pharmaceuticals shares are held by institutional investors. Comparatively, 32.5% of Galapagos shares are held by institutional investors. 4.2% of Jazz Pharmaceuticals shares are held by company insiders. Comparatively, 2.9% of Galapagos shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Jazz Pharmaceuticals presently has a consensus price target of $185.86, suggesting a potential upside of 65.94%. Galapagos has a consensus price target of $34.50, suggesting a potential upside of 26.10%. Given Galapagos' stronger consensus rating and higher possible upside, research analysts clearly believe Jazz Pharmaceuticals is more favorable than Galapagos.
Jazz Pharmaceuticals has a net margin of 8.61% compared to Jazz Pharmaceuticals' net margin of 0.00%. Galapagos' return on equity of 27.86% beat Jazz Pharmaceuticals' return on equity.
In the previous week, Jazz Pharmaceuticals had 7 more articles in the media than Galapagos. MarketBeat recorded 9 mentions for Jazz Pharmaceuticals and 2 mentions for Galapagos. Jazz Pharmaceuticals' average media sentiment score of 0.93 beat Galapagos' score of 0.87 indicating that Galapagos is being referred to more favorably in the news media.
Jazz Pharmaceuticals has higher revenue and earnings than Galapagos.
Jazz Pharmaceuticals received 637 more outperform votes than Galapagos when rated by MarketBeat users. Likewise, 80.51% of users gave Jazz Pharmaceuticals an outperform vote while only 64.54% of users gave Galapagos an outperform vote.
Summary
Jazz Pharmaceuticals beats Galapagos on 14 of the 16 factors compared between the two stocks.
Get Galapagos News Delivered to You Automatically
Sign up to receive the latest news and ratings for GLPG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GLPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Galapagos Competitors List
Related Companies and Tools
